AbbVie Announced FDA Approved the Use of Imbruvica for the Treatment of Pediatric Patients One Year and Older With cGVHD After Failure of One or More Lines of Systemic Therapy
AbbVie (NYSE: ABBV) today announced that the U.S. Food and Drug Administration (FDA) approved the use of IMBRUVICA® (ibrutinib) for the treatment of pediatric patients one year and older with chronic graft versus host disease (cGVHD) after failure of one or more lines of systemic therapy.
